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Abstract
 
Vascular cellular adhesion molecule
 
 
 
(VCAM)-1 is a membrane-bound cellular adhesion mole-
cule that mediates adhesive interactions between hematopoietic progenitor cells and stromal
cells in the bone marrow (BM) and between leukocytes and endothelial as well as dendritic
cells. Since VCAM-1–deficient mice die embryonically, conditional VCAM-1 mutant mice
 
were generated to analyze the in vivo
 
 
 
function of this adhesion molecule. Here we show that
interferon-induced Cre-
 
loxP–
 
mediated deletion of the 
 
VCAM-1
 
 gene after birth efficiently ab-
lates expression of VCAM-1 in most tissues like, for example, BM, lymphoid organs, and lung,
but not in brain. Induced VCAM-1 deficiency leads to a reduction of immature B cells in the
BM and to an increase of these cells in peripheral blood but not in lymphoid organs. Mature
recirculating B cells are reduced in the BM. In a migration assay, the number of mature B cells
that appears in the BM after intravenous injection is decreased. In addition, the humoral im-
mune response to a T cell–dependent antigen is impaired. VCAM-1 serves an important role
for B cell localization and the T cell–dependent humoral immune response.
 
Key words: conditional VCAM-1 mutant mice • B cell development • lymphocyte migration • 
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Introduction
 
The vascular cell adhesion molecule (VCAM)
 
1
 
-1 (CD106)
was originally described as a cytokine-induced glycoprotein
(INCAM-110) expressed on human vascular endothelial
cells (1). In mice, two isoforms of VCAM-1 are produced
by alternative splicing. One form contains seven Ig-like
 
domains, a transmembrane region, and a short COOH-
 
terminal cytoplasmic tail (2–4), while the second, cytokine
and LPS-inducible form, contains the first three domains
only and is attached to the cell membrane by a glycosylphos-
phatidylinositol anchor (5). VCAM-1 directs the recruitment
of leukocytes to sites of inflammation by binding predomi-
 
nantly to 
 
a
 
4
 
b
 
1 integrin (very late antigen [VLA]-4; CD49d/
CD29) and with lower affinity to 
 
a
 
4
 
b
 
7 integrin (6–8).
Binding of the seven domain form of VCAM-1 to its ligands
is mediated by the first and fourth Ig-like domain (9, 10).
 
A contribution of the VCAM-1/VLA-4 adhesion path-
way for leukocyte migration in rheumatoid arthritis, lupus
nephritis, inflammatory bowel disease, allograft rejection,
atheriosclerosis, contact hypersensitivity, and experimental
autoimmune encephalomyelitis has been suggested (11–18).
Blocking VCAM-1/VLA-4–mediated cellular adhesion by
mAbs often results in a less severe course of these diseases in
animal models.
Differentiation and proliferation of hematopoietic progen-
itor cells occur in intimate contact with the bone marrow
(BM) microenvironment which is composed of stromal cells
and extracellular matrix proteins. Since stromal cells secrete
numerous factors that are necessary for the growth and dif-
ferentiation of hematopoietic precursor cells, it may be
critical for these cells to stay in the BM in order to be ex-
posed to a cytokine milieu and to receive all signals neces-
sary for maturation. VCAM-1 is constitutively expressed
on BM stromal cells (19). Several reports demonstrate that
VCAM-1 plays a crucial role in hematopoietic progenitor
cell trafficking and lodgement of transplanted murine he-
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intercellular adhesion molecule; NP-CG, (4-hydroxy-3-nitrophenyl)-
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very late antigen. 
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Inducible Gene Targeting of VCAM-1
 
matopoietic progenitor cells to BM (19–22). Other authors
have shown the significance of cytokines for hematopoietic
progenitor cell (HPC) mobilization in vivo by the treatment
of mice with fms-like tyrosine kinase 3 (Flt3) ligand (23).
This suggests that cytokines may alter the expression or the
activation state of adhesion molecules. VCAM-1 is also
constitutively expressed on follicular dendritic cells (24, 25),
which serve a critical role for antigen presentation. The
VLA-4–VCAM-1 interaction is involved in the adhesion of
human B cells to follicular dendritic cells of germinal centers
in vitro, which is hypothesized to affect the immune re-
sponse maturation in the germinal center (24–27). Further-
more, a link between VCAM-1 function and rescue of ger-
minal center B cells (26–28) or thymocytes (29) from
apoptosis has been reported. Finally, VCAM-1 may also
function in maturation and costimulation of T cells (30–32).
 
Since mice homozygous for the 
 
VCAM-1
 
 deletion die
early during embryogenesis (33–35), most experiments re-
garding the function of VCAM-1 have so far been carried
out either in vitro or using mAbs blocking the function of
VCAM-1. A very small number of VCAM-1–deficient mice
survive the detrimental effects of the 
 
VCAM-1
 
 mutation on
embryogenesis (34). These mice exhibit elevated numbers of
circulating blood mononuclear leukocytes (34); however, no
phenotype with regard to hematopoiesis has been reported
(36). It remains questionable whether these mice represent a
suitable tool for evaluation of postnatal VCAM-1 function.
To circumvent the limitations of the above mentioned ap-
proaches for the evaluation of the in vivo function of
VCAM-1 for postnatal life, we used inducible gene targeting
(37). This approach leads to the absence of VCAM-1 protein
in most organs of mice in which the 
 
VCAM-1
 
 gene was de-
leted by IFN-induced Cre-loxP–mediated recombination.
Hereby, the critical function of VCAM-1 for retention of B
cells during maturation in the BM and for localization of
mature B cells in the BM could be established. Moreover,
VCAM-1 plays a critical role in the humoral immune re-
sponse to a T cell–dependent antigen.
 
Materials and Methods
 
Mice and Conditional Gene Inactivation.
 
Mice homozygous for
the 
 
loxP
 
 flanked (floxed) 
 
VCAM-1
 
 gene (35) and Mx-
 
cre
 
 trans-
genic mice (37) were bred and crossed to generate homozygous
 
VCAM-1
 
 floxed mice carrying the Mx-
 
cre
 
 transgene. In each lit-
ter, mice with and without the Mx-
 
cre
 
 transgene were generated.
Neonatally, at days 1, 4, and 7 the mice were injected with 10
 
6 
 
U
 
of IFN-
 
a
 
1/
 
a
 
2 intraperitoneally to inactivate the 
 
VCAM-1
 
 gene
in mice bearing the Mx-
 
cre
 
 transgene and to use the Mx-
 
cre
 
 non-
transgenic mice as controls. At the age of 5 wk, mice were typed
for the Mx-
 
cre
 
 transgene by 
 
Cre
 
-specific PCR and Southern blot
analysis. The different genotypes, Mx-cre;VCAM
 
flox/flox
 
 mice
(conditional VCAM-1 mutant mice) and VCAM
 
flox/flox
 
 mice
(control mice), were identified at the expected Mendelian ratio.
 
The mice were
 
 
 
kept in a conventional animal facility. Sentinel
animals were checked regularly according to the FELASA health
monitoring report (38) and mice were
 
 
 
used for studies at the age
of 6–8 wk to exclude any influence of IFN-
 
a
 
 treatment on the B
and T cell pool (39).
 
Southern Blot Analysis.
 
Tissue of different organs from condi-
tional VCAM-1 mutant mice was washed with PBS and digested
 
at 56
 
8
 
C with 100 
 
m
 
g/ml proteinase K (Boehringer) in lysis buffer
(100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% SDS) overnight.
1 vol of isopropanol was added to the lysate and the precipitate
was recovered. Depending on the size of the precipitate the DNA
was dispersed in 100–400 
 
m
 
l of 10 mM Tris-HCl, 0.1 mM
EDTA, pH 7.5. The prepared DNA was digested with BamHI
(New England Biolabs, Inc.) and probed with a mixture of two
 
650-bp 
 
VCAM-1
 
–specific SpeI-BglII (New England Biolabs,
Inc.) fragments of vector 2BAM (35) nonradioactive labeled with
the Gene Images™ labeling kit (Amersham Pharmacia Biotech).
In an agarose gel the deleted 
 
VCAM-1
 
 gene migrated at 4.5 kb,
whereas the floxed gene gave two signals of 6 and 3 kb in size.
To test mice for the presence of the Mx-
 
cre
 
 transgene tail,
DNA was digested with BamHI and probed with a 750-bp
BamHI-XbaI (New England Biolabs, Inc.) fragment of the Cre-
coding region, resulting in two bands at 5 and 3.5 kb.
 
Quantification of the Deletion.
 
To assess the degree of 
 
VCAM-1
 
gene deletion in various tissues, DNA from organs of three differ-
ent conditional VCAM-1 mutant mice was prepared and analyzed
by at least two independent Southern blot each. The amount of
deletion was calculated by scanning the signals of the 3-kb floxed
and the 4.5-kb deleted 
 
VCAM-1
 
 gene fragment generated during
different exposure times on X-OMAT film (Eastman Kodak Co.)
in a FluorS MultiImager (Bio-Rad Laboratories).
 
PCR.
 
To test for the presence of the Mx-
 
cre
 
 transgene, a 1-kb
fragment of the coding region was amplified by standard PCR
procedure using the two primers cre
 
2
 
 (5
 
9
 
-CAA TTT ACT
GAC CGT ACA C-3
 
9
 
) and cre
 
1
 
 (5
 
9
 
-CAT CGC CAT CTT
CCA GCA-G). Tissue from tail biopsies was lysed overnight at
56
 
8
 
C with 100 
 
m
 
g/ml proteinase K (Boehringer) in lysis buffer
(100 mM Tris-HCl, pH 8.5, 5 mM EDTA, 0.2% SDS), precipi-
tated with isopropanol, and resuspended in 150 
 
m
 
l Tris-HCl, 0.1
mM EDTA, pH 7.5. 1 
 
m
 
l of this DNA solution was used for
PCR analysis in 50 ml vol overlayed with mineral oil. 200 mM
dNTPs (Boehringer), 20 pmol of each primer, and 5 U Taq poly-
merase (produced in our own laboratory) were added, and the
PCR reaction was performed on a thermal cycler (TRIO-Ther-
moblock; Biometra) in 10 mM Tris-HCl, pH 8.3, at 25
 
8
 
C, 50
mM KCl, and 3 mM MgCl
 
2
 
 (35 cycles: 40 s at 94
 
8
 
C, 1 min at
60
 
8
 
C, and 1.5 min at 72
 
8
 
C). After the last cycle, samples were in-
cubated for another 10 min at 72
 
8
 
C and subsequently analyzed by
gel electrophoresis on a 1% agarose gel.
 
Immunoprecipitation.
 
Mice were killed and the prepared or-
gans were washed several times in PBS. Tissue was then homoge-
nized and cells were disrupted with glass beads (Braun-Melsun-
gen) in TBS (0.5% SDS, 1% Triton, 0.025 mM EDTA, 0.1 M
Tris, pH 8.0) containing protease inhibitors as described (40). Af-
ter adding 0.5% NP-40, membrane proteins were extracted at
4
 
8
 
C overnight. Cell debris was removed by high speed centrifu-
gation and 0.4 ml of the supernatant was subjected to immuno-
precipitation. After incubation with biotinylated goat anti–mouse
IgG1 Ab (Dianova) overnight at 4°C and precipitation of unspe-
cific bound proteins through adding streptavidin-coupled agarose
(Sigma-Aldrich) for another night at 4
 
8
 
C, preclearing was fin-
ished by centrifugation preceeding precipitation of VCAM-1
protein from the supernatant. For that purpose the supernatant
was incubated again overnight at 4
 
8
 
C with biotinylated rat anti–
mouse VCAM-1 Ab (Clone 429; BD PharMingen) after another
24 h at 4
 
8
 
C in the presence of streptavidin-coupled agarose and
precipitation by centrifugation. The pellet was washed two times
in PBS and separated on a 10% acrylamide gel. Proteins were 
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blotted on a PVDF membrane (Immobilon-P; Millipore) and
VCAM-1 protein was detected with polyclonal goat anti–
VCAM-1 Ab (sc-1504; Santa Cruz Biotechnology, Inc.) and
anti–goat IgG-horseradish peroxidase (Dako) using an ECL de-
tection kit (Amersham Pharmacia Biotech).
 
Immunohistochemistry.
 
Frozen sections of spleen were fixed in
acetone, incubated with 0.1% phenylhydrazine (Sigma-Aldrich) in
PBS, and blocked with PBS containing 4% FCS. For immu-
nostaining biotinylated rat anti–mouse VCAM-1 mAb (clone 429;
BD PharMingen), rat anti–mouse VCAM-1 mAb (MK-2, 9.DB3,
V.7H1, V.4B12.1, V.6C3; provided by Dr. D. Vestweber, Uni-
versity of Muenster, Muenster, Germany), or polyclonal goat anti–
VCAM-1 Ab (sc-1504; Santa Cruz Biotechnology, Inc.) was used.
Primary Abs were detected with peroxidase-conjugated streptavi-
din (Dianova) or peroxidase-conjugated anti–rat IgG (Jackson
 
ImmunoResearch Laboratories) or anti–goat IgG (Santa Cruz
 
Biotechnology, Inc.). The detection was performed using 3,3
 
9
 
-
diaminobenzidine (DAB) substrate kit (Pierce Chemical Co.).
 
Hematologic Analysis.
 
Blood samples were obtained from
mouse tail vein; EDTA served as an anticoagulant. Erythrocyte
and leukocyte counts were determined by an automatic cell
counter (Beckman Coulter). Differential counts were assessed
based on cellular morphology of blood smears by Wright-Giemsa
stain (Sigma-Aldrich) and in peripheral blood by four-color flow
cytometry using the following mAbs: PE-conjugated CD3e
(clone 145-2C11; BD PharMingen), allophycocyanin (APC)-
conjugated RA3-6B2 (anti–murine B220; references 41, 42),
biotinylated GR-1 (clone RB6-8C5; BD PharMingen),
FITC-conjugated F4-80 (Serotec), and streptavidin-CyChrome
(GIBCO BRL). Monocytes and neutrophils were further quanti-
 
fied by cytochemistry on blood smears. Naphthol-AS-
 
D
 
-chloro-
acetate esterase activity was used to identify neutrophils
 
 
 
(43)
while monocytes were characterized by their 
 
a
 
-naphthyl-acetate
esterase activity
 
 
 
(44).
 
Flow Cytometry.
 
Single cell suspensions from BM (femur)
were prepared by flushing bones with medium (DMEM; GIBCO
BRL), and for preparation of blood lymphocytes heparinized
blood was separated by a 7.5% Ficoll (GIBCO BRL) gradient.
Single cell suspensions from other organs were prepared by gentle
dissection of these tissues in medium. All cell suspensions were
subsequently incubated for 2 min on ice in erythrocyte lysis
buffer (140 mM NH
 
4
 
Cl, 17 mM Tris, pH 7.65) followed by
washing and resuspension in staining buffer (PBS supplemented
with 1% BSA and 0.1% NaN
 
3
 
). Cells present in the lymphocyte
gate, as defined by light scatter (45), were analyzed by three- and
four-color immunofluorescence on a FACScan™
 
 
 
(Becton Dick-
inson) or on a FACStar™ (Becton Dickinson) using the
CELLQuest™ program. Staining was done with fluorochrome
APC-, FITC-, PE-, or CyChrome- or biotin-conjugated mAbs.
Biotin-conjugated mAbs were detected using streptavidin-PE,
streptavidin-CyChrome, or Texas red–avidin (GIBCO BRL).
APC-conjugated RA3-6B2 (anti-murine B220; references 41,
42), PE-conjugated R33-24-12 (anti–murine 
 
m
 
; reference 46),
FITC-conjugated 1.3-5 (anti–murine IgD; reference 47), bio-
tinylated 493 (anti–murine pB130-140) Abs (48), and FITC-con-
jugated annexin V (BD PharMingen) or biotinylated annexin V
(Roche) were used for surface marker staining.
 
Short-term Migration Assay.
 
Splenocytes were prepared ac-
cording to standard procedures from CB20 mice (H-2
 
d
 
). 1.8 
 
3
 
10
 
9
 
 splenocytes were coupled to S7 beads (Miltenyi Biotec). De-
 
pletion of S7
 
1
 
 (CD43
 
1
 
) cells by MACS
 
®
 
 (49) using VS
 
1
 
 columns
resulted in 1.2 
 
3
 
 10
 
8
 
 mature B cells at 93% purity, which were
collected and stained with PKH-26 (Sigma-Aldrich). 3 
 
3
 
 10
 
7
 
stained cells were injected into the tail vein of control and condi-
tional VCAM-1 mutant mice, respectively. After 20 h, mice
were killed and lymphocytes from BM were prepared and ana-
lyzed by flow cytometry.
 
Immunization.
 
Mice 8–10 wk of age were immunized intra-
peritoneally with 100 
 
m
 
g alum-precipitated (4-hydroxy-3-nitro-
phenyl)-acetyl-chicken globulin (NP-CG) or 10 
 
m
 
g NP-Ficoll.
After 3 wk NP-CG–injected mice were boosted in the same
manner with 50 
 
m
 
g NP-CG. At days 0, 7, 14, 21, 28, and 35
(NP-CG immunization) or at days 0, 7, and 14 (NP-Ficoll im-
munization) mice were bled. The sera were analyzed by enzyme-
linked immunosorbent assays for NP-conjugated antigens (50).
Affinity maturation of serum IgG1 Ab was assessed in sera of NP-
CG–immunized mice by measuring the ratio of binding to NP
 
4
 
-
BSA/NP
 
14
 
-BSA (50). Germinal centers were stained in splenic
sections with biotinylated peanut agglutinin (Vector Laborato-
ries), detected with streptavidin–horseradish peroxidase (Di-
anova), developed with diaminobenzidine, and counterstained
with hematoxylin (Sigma-Aldrich) by standard procedure (51).
 
Quantification of Plasma Cells.
 
IgG-secreting plasma cells in
10-mo-old mice were stained with TRITC (rhodamine)-conju-
gated goat anti–mouse IgG mAb (Southern Biotechnology Asso-
ciates, Inc.) in cytospins of spleen and BM (52). Each cytospin
contained 2 
 
3
 
 10
 
5
 
 cells. At least 14 cytospins of two control and
two conditional VCAM-1 mutant mice were counted.
 
Bromodeoxyuridine Treatment.
 
Mice (two control and two
conditional VCAM-1 mutant mice) were fed with bromodeox-
yuridine (BrdU) at a concentration of 1 mg/ml with 1 M sucrose
in drinking water for 3 d. During the labeling period the drinking
water was protected from light. Mice were then killed and sur-
face staining of single cell suspensions was performed as described
previously
 
 
 
(53). 5–10 
 
3 106 cells were first surface stained with
FITC-conjugated Abs against B220 (mAb RA33.A1.CL6) or
IgM (mAb R33-24-12). After fixation in methanol and denatur-
ation of the DNA, cells were stained with a biotinylated anti-
BrdU Ab (Alexis Biochemicals), then incubated with streptavi-
din-CyChrome and analyzed by FACS®.
Statistical Analysis. Data are presented as mean 6 SEM. Statis-
tical significance of the results was assessed using the Student’s t test.
Results
Conditional Gene Targeting of VCAM-1. To circum-
vent embryonic lethality in VCAM-1– deficient mice (33,
34) we set out to delete the VCAM-1 gene in mice in a
conditional manner using the Mx-cre system (37). In this
approach the target gene is flanked by loxP sites and Cre is
expressed after IFN injection. This leads to a Cre-loxP–
mediated deletion of the target gene. We have crossed
mice in which the proximal promoter sequences and the
first two exons of the VCAM-1 gene are flanked by loxP
sites (VCAM-1flox/flox mice; reference 35), with Mx-cre
transgenic mice (37; Fig. 1 A). On days 1, 4, and 7 after
birth, mice homozygous for the VCAM-1 mutation and
transgenic for Mx-cre (Mx-cre;VCAMflox/flox mice) were
treated with 106 U IFN-a1/a2 (IFN-a) (54) to induce
Cre-mediated recombination. Mice were analyzed for de-
letion of the VCAM-1 gene at the age of 6–8 wk.
VCAM-1flox/flox mice (control mice) and Mx-cre;
VCAM-1flox/flox mice (conditional VCAM-1 mutant mice)
did not exhibit any detectable deletion of the VCAM-1758 Inducible Gene Targeting of VCAM-1
gene in spleen without IFN-a treatment. After IFN-a ap-
plication, VCAM-1 deletion was complete in the spleens
of conditional VCAM-1 mutant mice, while there was no
deletion detectable in control mice (Fig. 1 B). This sug-
gests that conditional targeting of the VCAM-1 gene using
the Mx-cre system is efficient and does not exhibit any ob-
vious leakiness either in the absence of IFN-a application
or in the absence of the transgene. After induced deletion,
conditional VCAM-1 mutant mice did not exhibit any
overt disease and could be kept for at least 12 mo. When
different organs were assessed by Southern blotting for de-
letion of the VCAM-1 gene in conditional VCAM-1 mu-
tant mice after IFN-a treatment, it became evident that
the extent of the deletion varied. While the deletion was
complete in, for example, BM, liver, lymph nodes, spleen,
and thymus, only partial deletion was observed in heart
(45%), intestine (85%), kidney (84%), and lung (69%), and
only minimal deletion could be detected in brain (16%;
Fig. 1 C).
To confirm that conditional deletion of the VCAM-1
gene led to a lack of protein expression, Western blot anal-
ysis for VCAM-1 protein and immunhistochemical detec-
tion using mAbs against VCAM-1 were performed. By
Western blot analysis, there was no VCAM-1 protein de-
tectable in BM, liver, lymph nodes, spleen, and thymus of
conditional VCAM-1 mutant mice after IFN-a treatment,
while a minor protein band was recognizable in the lung
and heart (Fig. 1 D). By contrast, abundant VCAM-1 pro-
tein with a molecular mass of z110 kD was present in the
brain of these mice, as expected from the results of the
Southern blot analysis (Fig. 1 C).
The immunohistochemical analysis confirmed the ab-
sence of VCAM-1 expression after conditional targeting of
the VCAM-1 gene. A set of anti–VCAM-1 mAbs binding
to different epitopes was used for indirect immunohis-
tochemical detection. Frozen tissue sections from spleens of
control mice after IFN-a treatment readily exhibited stain-
ing for VCAM-1 (Fig. 1 E). By contrast, no VCAM-1 ex-
pression was detectable in spleens of conditional VCAM-1
mutant mice after IFN-a application (Fig. 1 E).
Thus, the level of genomic deletion as assessed by South-
ern blot analysis corresponds well with the lack of protein
expression of VCAM-1 as measured by Western blot anal-
ysis or immunohistochemistry.
Figure 1. Efficient conditional ablation of VCAM-1 in
vivo. (A) Southern blotting strategy for detection of IFN-
a–induced  VCAM-1 gene deletion. (B) Southern blot
analysis of splenic DNA of mice without (lanes 1 and 2)
and with (lanes 3 and 4) IFN-a injection (probed for
VCAM-1). Without either the cre transgene (lanes 1 and 3)
or IFN-a induction (lane 2), deletion of the VCAM-1
gene did not occur, as indicated by the 3- and 6-kb bands.
By contrast, deletion is almost complete after IFN-a induc-
tion in the presence of the cre transgene (lane 4), resulting
in a 4.5-kb signal. (C) Southern blotting of various tissues
from IFN-a–treated, conditional VCAM-1 mutant mice
revealed a high degree of deletion in most organs, but almost no deletion in brain (LI, liver; LN, lymph node; LU, lung; SP, spleen; TH, thymus; BR,
brain; HE, heart; IN, intestine; KI, kidney). (D) Western blot analysis of VCAM-1 (110 kD) in conditional VCAM-1 mutant and control mice. After
IFN-a–induced Cre expression, VCAM-1 could not be detected in BM, liver, lymph node, spleen, and thymus of conditional VCAM-1 mutant mice
(lanes 4, 6, 8, 10, and 11), while minor traces of VCAM-1 are detectable in heart, intestine, and lung (lanes 2, 5, and 7) and brain contains VCAM-1 levels
similar to control mice (lane 1). (E) Immunohistochemical analysis of spleen reveals VCAM-1 expression in control mice (left) and by contrast, no
VCAM-11 cells in spleen of conditional VCAM-1 mutant mice (right).759 Leuker et al.
VCAM-1 Retains Immature B Cells in the BM. Spleen,
lymph nodes, thymus, and BM from IFN-treated condi-
tional VCAM-1 mutant mice and from IFN-treated con-
trol mice were analyzed for cellularity and lymphocyte sub-
sets by flow cytometry. While there was no major
difference in overall cell number and expression of B220,
IgM, IgD, CD3, CD4, and CD8 in spleens, lymph nodes,
and thymus, a marked alteration of B cell subset distribu-
tion was detected in BM. There was a consistent, but statis-
tically not significant, small reduction of nucleated cells in
the BM of conditional VCAM-1 mutant mice (1.5 6
0.64 3 107 nucleated cells per femur for control mice,
1.2 6 0.41 3 107 nucleated cells per femur in conditional
VCAM-1 mutant mice, P = 0.27). However, the percent-
ages of cells within the lymphocyte gate were similar
(32.5  6 5.6% in control mice and 33.4 6 6.3% in condi-
tional VCAM-1 mutant mice), whereas the fraction of
B2201 cells within these gates is slightly reduced in
VCAM-1–deficient animals (14.7 6 3.7% in control mice
versus 10.6 6 2.9% in conditional VCAM-1 mutant mice,
P , 0.05). Taken together, this results in a reduced abso-
lute number of B2201 cells per femur in BM of conditional
VCAM-1 mutant mice (1.4 6 0.6 3 106 B2201 cells per
femur) compared with control mice (2 6 0.5 3 106 B2201
cells per femur, P , 0.05). Hardy et al. have developed a
nomenclature to distinguish the different stages of B cell
development, with the most immature pro-B cells present
in fraction A while mature B cells establish fraction F (42).
In conditional VCAM-1 mutant mice fraction E, which
comprises the immature B cells expressing IgM but no IgD,
is reduced by a mean of 40% compared with fraction E in
control mice (Fig. 2 A). This reduction of fraction E is
even more pronounced when absolute cell numbers are
calculated since the overall cell number and the number of
B2201 cells are reduced in conditional VCAM mutant
mice (see above; Fig. 2 B).
Fraction E cells comprise immature B cells that will soon
leave the BM to enter the blood. Therefore, we wondered
whether this B cell subset, which was reduced in the BM of
conditional VCAM-1 mutant mice, would be detectable
outside of the BM. In peripheral blood from conditional
VCAM-1 mutant mice an increased number of white
blood cells (16.3 6 3.9 3 103/mm3 blood versus 7.2 6 1 3
103/mm3 blood in control mice) was detected compared
with control mice. The ratio between lymphocytes, neu-
trophils, and monocytes, as well as the fraction of B2201
cells within the lymphocyte gate, was not significantly al-
tered (Table I). These findings are in accordance with ex-
periments of anti–VLA-4 treatment in primates leading to
granulocytosis as well as lymphocytosis (20, 21), whereas
blocking of VLA-4 in rats caused a strong increase of
mononuclear leukocytes and only a minor increase of poly-
morphonuclear leukocytes (55). However, in conditional
VCAM-1 mutant mice there was a dramatic increase of
IgM1IgD2 B cells (Fig. 3), a fraction of cells that could pos-
sibly represent the fraction E cells found to be diminished
in the BM (Fig. 2, A and B). 30.5 6 5.1% of all B2201 cells
in conditional VCAM-1 mutant mice compared with 14.9 6
1.8% of all B2201 cells in control mice belonged to the
fraction of immature IgM1IgD2 B cells in peripheral blood
(Fig. 3). This translates into a 3.5-fold increase of this popu-
lation with regard to absolute cell numbers (1.72 6 0.41 3
103/mm3 blood in conditional VCAM-1 mutant mice ver-
sus 0.49 6 0.04 3 103/mm3 blood in control mice). In ad-
dition, about threefold elevated levels of B2201IgM2IgD2
B cells, which may comprise B cells earlier during develop-
Figure 2. Altered B cell subsets in BM of
conditional VCAM-1 mutant mice. (A)
Flow cytometric analysis of BM cells within
the lymphocyte gate (reference 45). B lineage
cells are displayed by their CD45R/B220 and
IgM expression. The letters in the rectangles
indicate the different developmental stages
according to Hardy et al. (reference 42).
Conditional VCAM-1 mutant mice exhibit
reduced numbers of B cells in fraction E and
fraction F. 20,000 events were collected for
both of the dot plots. More than 10 mice
for both genotypes were analyzed, of which one representative experiment is depicted. (B) Compari-
son of absolute B cell numbers/femur (6 SEM) between conditional VCAM-1 mutant mice (gray
bars) and control mice (white bars). Values are calculated from four independent experiments including
8 control and 11 conditional VCAM-1 mutant mice. *Significantly different from value in control
mice, P , 0.05.760 Inducible Gene Targeting of VCAM-1
ment than fraction E, were detectable in peripheral blood
of conditional VCAM-1 mutant mice (0.32 6 0.13 3 103/
mm3 blood in mutant mice versus 0.11 6 0.04 3 103/mm3
blood in control mice).
Taken together, there is a sizeable shift in the peripheral
blood B cell pool of conditional VCAM-1 mutant mice to-
wards the more immature cells. This shift goes along with
the loss of fraction E cells in the BM, which led us to hy-
pothesize that VCAM-1 may be important for retention of
B lineage cells during development in BM until they reach
a certain developmental stage.
In contrast, the distribution of T cells was not signifi-
cantly altered in conditional VCAM-1 mutant mice. T cell
subsets (CD3, CD4, CD8) in thymus, spleen, peripheral
blood, and lymph nodes were similar in conditional
VCAM-1 mutant mice and control mice (data not shown).
B Cells Accumulating in the Blood of Conditional VCAM-1
Mutant Mice Are Immature Emigrants from the BM. Re-
cently a novel mAb called 493 has been described which
binds to a surface protein designated pB130-140 (48). This
Ab discriminates between long-lived recirculating 4932 B
cells and various stages of B cell development, including
fraction E cells which are either inside the BM or have just
left this site and still express pB130-140. Since the reduc-
tion of B cells in the BM is accompanied by an increase of a
similar B cell fraction in blood, we examined the origin of
these B cells in blood according to their pB130-140 ex-
pression. As predicted, the fraction of 4931 cells within
the lymphocyte gate in peripheral blood of conditional
VCAM-1 mutant mice was almost doubled compared with
control mice (Fig. 4 A). A strong increase of the absolute
number of 4931IgM1IgD2 B cells and a minute increase of
the 4931B2201IgM2IgD2 B cells were noted (Fig. 4 B).
We evaluated whether immature B cells would also be
detectable at higher numbers in spleens of conditional
Table I. Peripheral Blood Counts
Blood cell types Control
Conditional
VCAM-1 mutant
Fold
increment  P value 
RBCs (106/mm3) 8.7 6 0.1* 8.0 6 0.6 0.9 0.13‡
Hemoglobin (g/dl) 14.2 6 0.4 14.1 6 0.7 1.0 0.92
WBCs (103/mm3) 7.2 6 1.0 16.3 6 3.9 2.3 0.008
L (% of WBCs) 71.9 6 13.4 70.1 6 11.3
B cells (% of L) 54.5 6 0.5 51.2 6 2.2
T cells (% of L) 37.3 6 6.0 32.2 6 4.1
N (% of WBCs) 19.9 6 3.2 20.6 6 4.8
M (% of WBCs) 3.5 6 0.8 3.4 6 0.4
E (% of WBCs) 1.6 6 1.2 2.4 6 1.2 
Ratio L/N/M/E 45:12:2:1 44:13:2:1.5
Hemoglobin levels as well as numbers of erythrocytes and leukocytes were evaluated in three control and seven mutant mice. E, eosinophils; L,
lymphocytes; M, monocytes; N, neutrophils; WBC, white blood cell.
*SEM.
‡Student’s t test.
Figure 3. Increased number of immature B cells in peripheral blood of
conditional VCAM-1 mutant mice. Flow cytometric analysis of periph-
eral blood B cells. In each experiment 20,000 events were acquired and
subsequently gated for B cells (CD45R/B2201 cells). The dot blots rep-
resent the CD45R/B2201 cells within the lymphocyte gate in a control
(top) and a conditional VCAM-1 mutant mouse (bottom) displayed by
their IgM and IgD surface expression. In addition, the frequencies
of mature (IgM1IgD1), immature (IgM1IgD2), and B220 only
(IgM2IgD2) B cells are depicted as percentages of all B2201 cells. More
than 15 mice for both genotypes were analyzed, of which one represen-
tative experiment is shown.761 Leuker et al.
VCAM-1 mutant mice. 10–20% of the immature B cells
are supposed to reach the spleen as 4931 cells (48); how-
ever, the subsets of 4931 immature B cells have similar sizes
in spleens of conditional VCAM-1 mutant mice and con-
trol mice. Compared with blood there is only a modest in-
crease of 4931IgM1 cells detectable in spleens of VCAM-1
deficient mice (Fig. 4 C). There are several possible expla-
nations: 4931 cells in peripheral blood of conditional
VCAM-1 mutant mice have a reduced half life, 493 ex-
pression on these cells is rapidly downregulated, or, alterna-
tively, these cells get trapped in sites other than the spleen.
To determine the transit time of IgM1 cells from BM to
blood and spleen, we performed BrdU labeling of dividing
cells. After a labeling period of 3 d, we recovered 21 6
Figure 4. Expression of 493, a marker for immature
B cells, on peripheral blood B cells. (A) Increased
number of 4931IgM1 B cells in peripheral blood of
conditional VCAM-1 mutant mice was detected. In
each experiment, 50,000 events were acquired. The
upper dot blots represent peripheral blood cells in a
control (left) and a conditional VCAM-1 mutant
mouse (right) to indicate gating for lymphocytes. The
bottom displays the cells within the lymphocyte gate
by their IgM and 493 surface expression. The frequen-
cies of IgM24931, IgM14931, and IgM14932 cells are
depicted as percentages of all lymphocytes. Out of
three experiments, one representative flow cytometric
study including three control and seven conditional
VCAM-1 mutant mice is shown. (B) The graph illus-
trates the increase of 4931 B cells in peripheral blood
of conditional VCAM-1 mutant mice compared with
control mice. The mean absolute cell counts for leu-
kocytes and lymphocytes determined in a separate ex-
periment were used to calculate absolute numbers for
the B cell subsets. White bars represent control mice;
gray bars represent conditional VCAM-1 mutant mice.
(C) Number of 4931 cells in spleen of two control
mice (white bars) and two conditional VCAM-1 mu-
tant mice (gray bars) are shown as a percentage of all
lymphocytes. Immature IgD2 B cells are identified by
their IgM surface expression, and mature B cells ac-
cording to their IgD1 staining. Values are depicted with
the SEM from the flow cytometric analysis. *Signifi-
cantly different from value in control mice, P , 0.05.762 Inducible Gene Targeting of VCAM-1
7.9% IgM1BrdU1 cells in BM, 20.8 6 1.2% in blood, and
26.8 6 1.2% in spleen of control mice (as percentage of all
B2201 cells). In contrast, conditional VCAM-1 mutant
mice showed lower numbers of IgM1BrdU1 cells in BM
(15.8 6 4.2%) and increased amounts in blood (28.6 6
2.1%) and spleen (33.3 6 3.4%). If absolute cell numbers
are considered, the increase of newly generated IgM1 cells
in the blood of conditional VCAM-1 mutant mice is even
higher. Taken together, these results suggest that the
IgM1IgD2 B cells in peripheral blood of conditional
VCAM-1 mutant mice are recent emigrants from the BM.
Apoptosis of Immature B Cells in the Periphery. Although
the immature B cell compartment in blood is enlarged by
premature transit of these cells from the BM (Fig. 4, A and
B), no significant increase in immature B cells was observed
in spleen (Fig. 4 C) or lymph nodes of conditional VCAM-1
mutant mice. Since increased apoptosis of B cells in blood
could account for this observation, we quantified the num-
ber of apoptotic cells in the peripheral blood. In both control
mice and conditional VCAM-1 mutant mice, z12% of the
IgM1 cells were stained with annexin V (data not shown).
Therefore, the frequency of apoptotic B cells does not seem
to differ in blood from mutant and control animals.
Recirculation of Mature IgM1IgD1 B Cells into the BM Is
Influenced by VCAM-1 Expression. In addition to the pre-
mature loss of immature B cells from the BM into the
blood, we also observed a phenotype of the VCAM-1 defi-
ciency for mature recirculating B cells. Fraction F cells in
the BM were reduced by z63% compared with control
mice. These cells are mature B cells expressing IgM and
IgD, which are thought to recirculate from the periphery
into the BM (56). The number of fraction F cells signifi-
cantly decreased from 2.4% (0.31 6 0.06 3 106 cells per fe-
mur) in control mice to 0.9% (0.12 6 0.1 3 106 cells per
femur) of all nucleated cells in conditional VCAM-1 mu-
tant mice (Fig. 2, A and B). We hypothesized that VCAM-1
may play a role in mediating migration of mature B cells
into the BM. To address this we performed a short-term
migration assay of mature B cells. Splenocytes of control
mice were isolated and the immature CD431 cells were de-
pleted by MACS®. Enriched CD432 splenocytes, consist-
ing mainly of IgM1IgD1 B cells, were labeled with PKH-
26 and injected into the tail veins of conditional VCAM-1
mutant mice and control mice. First, in control mice we
were readily able to detect PKH-26–labeled mature B cells
in the BM after 20 h (rectangle FD in Fig. 5, left dot plot),
which supports the idea that mature B cells enter the BM.
More important, about half of the PKH-26–labeled cells,
which were detectable in BM of control mice, were found
in BM of conditional VCAM-1 mutant mice (Fig. 5). The
reduced number of PKH-26–labeled mature B cells that
were detected in the BM of conditional VCAM-1 mutant
mice after cell transfer in size parallels the observed reduc-
tion of fraction F (which is depicted by the rectangle F in
Fig. 5, right dot plot) in these animals. This could be ex-
plained by an impaired recirculation of mature B cells into
the BM caused by VCAM-1 deficiency. However, we can-
not rule out other possible explanations for this phenotype:
for example, an increasing loss of mature IgD1 B cells from
the BM or a rapid death of these cells in BM as a result of
the VCAM-1 deficiency. In addition, the short-term mi-
gration assay in the mutant animals might be influenced by
the leukocytosis present in these mice: competition of the
PKH-26–labeled cells with leukocytes present in the blood
stream might affect the efficiency of PKH-26–labeled cells
to enter the BM. The latter explanation is unlikely, as
short-term migration assays performed with total spleno-
cytes did not show any differences with regard to lympho-
cyte homing to spleen and peripheral lymph nodes in mu-
tant and control mice, while the impaired recirculation to
BM was confirmed (preliminary data not shown).
Conditional VCAM-1 Mutant Mice Exhibit an Impaired T
Cell–dependent Humoral Immune Response. To investigate
whether the function of B cells is affected by the VCAM-1
deficiency, mice were immunized with NP-CG. The spe-
cific immune response in conditional VCAM-1–deficient
mice and control mice was monitored by measuring the
NP-specific Ig levels at different time points. Before immu-
nization, slightly but not significantly reduced levels of IgA,
IgM, IgG1, IgG2a, IgG2b, and IgG3 were detected in sera
of conditional VCAM-1 mutant mice (data not shown).
Upon NP-CG immunization, conditional VCAM-1 mu-
tant mice exhibited impaired primary and greater than five-
fold reduced secondary IgG1 responses compared with
control mice (Fig. 6). Affinity maturation of the Ab re-
sponse against NP and generation of germinal centers in
conditional VCAM-1 mutant mice did not seem to be af-
fected (data not shown; see Materials and Methods). In ad-
dition, the numbers of IgG secreting plasma cells in BM
and spleen of control and VCAM-1 deficient mice did not
show any significant difference. 10-mo-old control mice
contained 230 6 85 IgG-secreting plasma cells/2 3 105
cells in BM and 77 6 17 IgG-secreting plasma cells/2 3
105 cells in spleen, versus 247 6 90 in BM and 75 6 21 in
Figure 5. Short-term migration of mature B cells into the BM. Flow
cytometric analysis of CD45R/B2201 gated lymphocytes in BM of con-
trol mice and conditional VCAM-1 mutant mice 20 h after injection of
mature splenic PKH-26–labeled B cells. The BM B cells are displayed by
their IgD surface and PKH-26 expression. Rectangle FD contains the do-
nor-derived, PKH-26–labeled, recirculating mature B cells; rectangle F
represents the fraction F of mature B cells present in the host. 0.06 6
0.011% of all acquired events were recirculating B2201PKH-261IgD1 B
cells in control mice, while only 0.03 6 0.01% of such cells were recov-
ered from conditional VCAM-1 mutant BM. In total, 200,000 events
were acquired for each dot plot; four control mice and four conditional
VCAM-1 mutant mice were analyzed in two independent assays, of
which one representative pair of mice is shown.763 Leuker et al.
spleen of conditional VCAM-1 knockout mice. Although
the generation of an efficient humoral immune response to
a T cell–dependent antigen is dependent on VCAM-1, we
could not distinguish whether this effect of the VCAM-1
deficiency is caused by an intrinsic B cell defect or is due to
a defect in T and B cell interaction. Interestingly, when
conditional VCAM-1 mutant mice were immunized with
NP-Ficoll, which serves as a T cell–independent antigen,
the immune responses were similar in mutant and control
mice (anti-NP l preimmune levels less than 0.08 mg/ml in
mutant and control mice; 14 d after immunization 47 6
6.2 mg/ml in control and 46.1 6 22.8 mg/ml in condi-
tional VCAM-1 mutant mice).
Discussion
To study the in vivo function of the VCAM-1 gene,
conditional VCAM-1 mutant mice were generated, since
conventional gene targeting of VCAM-1 had resulted in
embryonic lethality. VCAM-1flox/flox mice (here control
mice) and conditional VCAM-1 mutant mice are viable,
and VCAM-1flox/flox mice expressed similar levels of
VCAM-1 compared with wild-type mice (35). After IFN-a
induced Cre expression (37), the loxP-flanked VCAM-1 al-
leles were efficiently deleted in BM, liver, lymph nodes,
spleen, and thymus. Southern blot analysis revealed almost
complete deletion for VCAM-1 in these tissues and lower
efficiency of deletion in heart, intestine, kidney, and lung
(Fig. 1 C). In accordance with the marginal IFN-induced
Cre expression in the brain of Mx-cre transgenic mice (37)
there was only poor VCAM-1 deletion in the brain of con-
ditional VCAM-1 mutant mice, probably caused by limited
accessibility of this compartment for IFN-a (57). In addi-
tion, we confirmed the deficiency of VCAM-1 protein af-
ter induced deletion by Western blot analysis and by im-
munohistochemistry using various VCAM-1–specific Abs
(Fig. 1, D and E). With respect to the large amounts of im-
munoprecipitated VCAM-1 protein detectable in control
mice (Fig. 1 D), we cannot exclude that VCAM-1 expres-
sion is upregulated by the neonatal treatment of these mice
with IFN-a, which would be similar to the induction of
VCAM-1 expression by IFN-a in humans (58).
We studied the role of VCAM-1 for hematopoiesis in
conditional VCAM-1 mutant mice. In accordance with
studies using mAbs that block VLA-4 function (20) a
greater than twofold increase of the white blood cells was
detected in the mutants. However, in contrast to the studies
by Papayannopoulou et al. (20) and to the results obtained
from mice with reduced VCAM-1 expression (36), we ob-
served an altered distribution of immature and mature B
cells in BM and peripheral blood of conditional VCAM-1
mutants. The strong increase of B2201IgM1 B cells in
blood is paralleled by a loss of immature B cells (fraction E)
from the BM. The expression of pB130-140 by these im-
mature B cells as recognized by the 493 Ab suggests that
they originate from the BM (Fig. 4, A and B). This in-
terpretation is further supported by the increase of
BrdU1IgM1 B cells in the blood of conditional VCAM-1
mutant mice after a labeling period of 3 d, which is accom-
panied by a modest decrease of these cells in BM of
VCAM-1–deficient mice. These results describe a novel
function for VCAM-1: retention of B cells at late develop-
mental stages (i.e., B2201IgM1IgD2 immature B cells) in
the BM. The loss of immature B cells from BM and their
accumulation in peripheral blood resembles data obtained
from mice reconstituted with CXC chemokine receptor
(CXCR)4-deficient fetal liver cells (59). However, there
are also differences in the phenotypes of conditional
VCAM-1 mutants and mice reconstituted with CXCR4-
deficient fetal liver cells. While conditional VCAM-1 mu-
tant mice exhibit the most dramatic changes in the fraction
of immature B cells in the BM, the B cell progenitors and
the pre-B cells are mainly affected in mice reconstituted
with CXCR4-deficient fetal liver cells as well as in mice
with a deletion of the CXCR4 ligand, stromal cell–derived
factor 1 (SDF-1; reference 60). A contribution of SDF-1 for
migration of hematopoietic progenitor cells into the BM by
activation of the VLA-4/VCAM-1 adhesion pathway has
already been shown in vitro (61). Interestingly, the VCAM-1
and CXCR4 mutations have in common that they specifi-
cally affect B cells, while the T cell compartment so far has
not been shown to be altered by either mutation.
CD24 heat stable antigen (HSA)–deficient mice also ex-
hibit a phenotype that shares features of the VCAM-1 defi-
ciency. Fraction E cells are significantly reduced in the BM
of CD24-deficient mice; however, there are no data avail-
able on whether these cells appear in peripheral blood.
Figure 6. T cell–dependent immune response. Anti–NP-IgG1 levels
in sera from control mice (white bars) and from conditional VCAM-1
mutant mice (gray bars) are depicted over 35 d after immunization. Two
independent experiments were performed. The values shown were
calculated from one experiment including three control mice and eight
conditional VCAM-1 mutant mice. *Significantly different from value in
control mice, P , 0.05.764 Inducible Gene Targeting of VCAM-1
Nielsen et al. have interpreted their findings as a leaky
block in B cell development (62). Since another study has
reported that CD24 HSA expression is a prerequisite for
VLA-4/VCAM-1–mediated adhesion of pre-B cells to en-
dothelioma cells (63), one may speculate that the mutation
of VCAM-1 as well as of CD24 HSA both affect a com-
mon pathway which mediates retention of immature B
cells in the BM.
Apart from the altered distribution of B cells between
BM and peripheral blood in conditional VCAM-1 mutant
mice, the development from pre-B cells to mature IgD1 B
cells does not seem to be affected, given that we detected
similar numbers of mature B cells in lymph nodes and
spleen of conditional VCAM-1 mutant and control mice.
Therefore, it may be that only a limited number of imma-
ture B cells, which are increased in blood of conditional
VCAM-1 mutant mice, undergoes transition to mature B
cells. We cannot rule out that these immature B cells are
functionally not equivalent to the immature B cells in
blood of control mice. Whether immature B cells in condi-
tional VCAM-1 mutant mice possess the same ability to re-
new the mature B cell pool like immature B cells in control
mice, which have spent a longer time in the BM, and
whether they exhibit the same half-life and homing prop-
erties are still unknown. It has recently been suggested that
the size of the peripheral mature B cell pool is autono-
mously regulated with the priority to maintain normal IgM
serum levels and is not a direct function of the number of
available B cell precursors (64). This mechanism may keep
the mature B cell pool constant in the conditional VCAM-1
mutant mice as well, as these mice exhibit normal Ig levels.
The immature B cells in blood, which are not used to re-
plenish the mature B cell pool of conditional VCAM-1
mutant mice, may leave the blood and may either be
trapped or die in other compartments. However, immature
B cells do not accumulate in significant numbers in spleen
or lymph nodes of mutant mice. In addition, we could not
show that B cells undergo apoptosis in blood at significantly
higher rates than in control animals. In general, similar
statements apply also for T cells, e.g., enlarged amounts of
T cells in peripheral blood, but no increased amounts of
apoptotic T cells in blood or higher T cell numbers in sec-
ondary lymphoid tissues of young mice.
During fetal life b1 integrins are critical for hematopoie-
sis (65) and B and T cell development postnatally depends
on a4 integrin (63, 66, 67). a4 integrin mediates efficient
attachment and transmigration of pre-B cells beneath the
BM stroma, which seems to be important for B cell devel-
opment. In the absence of a4 integrin, B and T cell devel-
opment is still possible, albeit at a very inefficient rate (67);
B cell development in a4 integrin-deficient chimeric mice
is impaired before the pro-B cell stage (66). By contrast,
our data suggest that B and T cells can develop in the ab-
sence of the a4b1 integrin ligand, VCAM-1. We therefore
hypothesize that, while VCAM-1 mediates retention of
immature B cells in the BM, other ligands of a4 integrin
serve additional functions during lymphopoiesis. The role
of the a4 integrin ligand fibronectin for localization of
HPCs is still controversial. In one study, treatment with re-
agents blocking binding to fibronectin (connecting se-
quence-1 [CS-1] inhibitor, mAbs against a5b1) did not
lead either to an increase in the number of HPCs in periph-
eral blood or to a reduction of HPCs in BM (22), while a
different study revealed increasing numbers of HPCs by in-
travenous injection of blocking peptides for all three pri-
mary fibronectin-binding sites (68). The expression of fms-
like tyrosine kinase 3 (Flt3) ligand and IL-3 receptor on
early B lineage cells and the in vitro finding that through
these receptors binding of VLA-4 and VLA-5 to fibronec-
tin is augmented (69, 70) support the idea that particularly
early developmental stages of B lineage cells may depend
on interaction with BM stromal cells via fibronectin.
An additional important observation in the BM of con-
ditional VCAM-1 mutant mice is the reduction of the ma-
ture B cells (fraction F) in this compartment (Fig. 2, A and
B). Short-term migration assays confirmed the hypothesis
that in mice mature B cells recirculate from the peripheral
blood to the BM, and showed that in the absence of
VCAM-1 the lodgement of mature B cells to the BM is
impaired (Fig. 5). Therefore, VCAM-1 not only plays a
role in recruitment of HPCs to the BM, as recently shown
(71), but is probably also involved in the recirculation of
mature B cells from peripheral blood to BM. This is sup-
ported by recent findings of Koni et al., who have shown
that migration of mature B cells into the BM is also im-
paired in TIE2Cre;VCAM-1flox/D  mice (72). The func-
tional significance of this recirculation of mature B cells to
the BM is still unclear.
Taken together, our results show that in addition to the
already described function of VCAM-1 for hematopoietic
progenitor localization VCAM-1 plays a crucial role for the
ordered trafficking of immature B cells and mature B cells
between BM and periphery. Since, apart from the leukocy-
tosis in peripheral blood (Table I), the observed conse-
quences of the conditional VCAM-1 mutation exclusively
affect B cells but not T cells (see Results), one can speculate
that during lymphoid development VCAM-1 expression in
BM becomes important for lymphocyte retention subse-
quent to the stage of a common lymphoid progenitor cell
and after the division into T and B cell lineage commitment.
mAbs against either intercellular adhesion molecule
(ICAM)-1, CD54, or VCAM-1 inhibit binding of human
germinal center B cells to follicular dendritic cells in vitro
(25). Moreover, ligation of the B cell receptor augments the
adhesion of B cells to VCAM-1 and fibronectin in germinal
centers by c-Met induction (73). The expression of VCAM-1
on follicular dendritic cells and the possible role of VCAM-1
for costimulation of T cells raised the question of whether
deletion of VCAM-1 would have an impact on the immune
response to a T cell–dependent antigen in vivo. The struc-
turally related adhesion molecule ICAM-1, which in vitro
had also been shown to participate in germinal center inter-
actions and to function as a costimulatory molecule for T
cells (25, 74), does not seem to participate in the humoral
immune response. ICAM-1–deficient mice generate normal
Ab responses to immunization with OVA (75). By contrast,765 Leuker et al.
VCAM-1 is necessary for an efficient immune response
against a T cell–dependent antigen, as shown after immuni-
zation of conditional VCAM-1 mutant mice (Fig. 6).
Blocking the VLA-4/VCAM-1 adhesion pathway has
been demonstrated to increase apoptosis in human germinal
center B cells (27). Therefore, VCAM-1 deficiency could
also have affected affinity selection of B cells. However, we
were unable to detect a difference in affinity maturation be-
tween conditional VCAM-1 mutant mice and control mice
(data not shown). In addition, B cells in mutant animals were
capable of mounting a robust T cell–independent humoral
immune response (see Results). The impaired T cell–depen-
dent humoral immune response could be explained by sev-
eral mechanisms: B cell migration within the germinal center
might be affected, and attachment of B cells to follicular den-
dritic cells might be impaired, leading to inefficient B cell
proliferation. Alternatively, T cell help for mounting a hu-
moral immune response might be impaired due to a lack of
VCAM-1–mediated costimulation. Finally, recirculation of
antigen-specific B cells to secondary lymphoid organs lead-
ing to a sustained immune response might depend on
VCAM-1. We favor the idea that the reduced humoral im-
mune response may be because of the absence of VCAM-1
expression on dendritic cells. At least IgG-secreting plasma
cells are present in similar numbers in spleen and BM of con-
trol and mutant mice. Therefore, it is unlikely that an im-
paired migration of plasma cells to BM could explain the re-
duced humoral immune response in these mice.
In conclusion, the Mx-cre/loxP system can be used to
inducibly delete genes which are expressed in endothelial
cells. This approach was used to elucidate the in vivo func-
tion of VCAM-1 for B cell localization and humoral im-
mune responses. We have detected a novel role for
VCAM-1 in addition to its already known function for
HPC migration, namely, its involvement in B cell homeo-
stasis in BM and peripheral blood. VCAM-1 mediates re-
tention of immature B cells in the BM and is probably in-
volved in the recirculation of mature B cells from blood to
the BM. Finally, VCAM-1 is critical for the T cell–depen-
dent humoral immune response.
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